Dr Reddy's Laboratories Analyst Ratings
BofA Securities Maintains Dr Reddy's Laboratories Ltd(RDY.US) With Buy Rating
Dr Reddy's Laboratories Analyst Ratings
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81
Dr Reddy's Laboratories Analyst Ratings
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $70
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating
Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $66
Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 From $68, Maintains Overweight Rating
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $69
Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating
Dr Reddy's Labs Price Target Cut to $68.00/Share From $70.00 by Barclays
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $68
Dr. Reddy's Laboratories Target Price Raised to INR4,750 From INR4,500 by Axis Securities